Drug Trial Radar · NCT00200499
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients
Last checked: Nov 20, 2026Latest source record: Dec 16, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
845
Actual
Start
Mar 2002
Primary completion
Not stated
Study completion Sep 2003
Sponsor
- Lead sponsor
- Mylan Bertek PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305. Nebivolol was studied as monotherapy and in conjunction with add-on antihypertensive therapy.
Conditions
- Hypertension
Interventions
NebivololDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in average sitting diastolic blood pressure measured at trough drug plasma level at the end of the extension phase compared to baseline of NEB 202, NEB 302 or NEB 305.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.